InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
6
Disclosed sells
2
T+90 hit rate
40%
T+90 mean return
+1.5%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Todisco Joseph, Chairman & CEO. Director active across 2 companies, notably Amneal Pharmaceuticals, Inc.. Aggregated, 21 filings have been logged. Split: 6 buys · 2 sells. Total volume traded: €238k. History available since 2 December 2021. The latest transaction was disclosed on 1 April 2025 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations21 total
59,170 shares@ US$3.3819.8% of flowCommon StockSEC:0001213900-25-027598:0
187,500 shares0Common StockSEC:0001213900-25-005675:0
17,829 shares@ US$11.1920.7% of flowCommon StockSEC:0001213900-25-003534:0
26,982 shares@ US$5.1713.8% of flowCommon StockSEC:0000899140-24-000577:0
13,561 shares@ US$3.745.0% of flowCommon StockSEC:0000899140-24-000302:0
Ideal exit: 8 Dec 2024 (T+270)
133,333 shares0Common StockSEC:0000929638-24-000131:0
10,000 shares@ US$3.713.7% of flowCommon StockSEC:0000929638-23-002490:0
Ideal exit: 4 Jun 2024 (T+270)
5,000 shares@ US$4.582.3% of flowCommon StockSEC:0000929638-23-001527:0
Ideal exit: 11 Feb 2024 (T+270)
5,000 shares@ US$4.582.3% of flowCommon StockSEC:0000929638-23-001517:0
37,443 shares@ US$5.3019.3% of flowCommon StockSEC:0000929638-23-001441:0
20,000 shares@ US$3.827.9% of flowCommon StockSEC:0001213900-22-073225:0
Ideal exit: 12 Aug 2023 (T+270)
4,700 shares@ US$3.922.0% of flowCommon StockSEC:0001213900-22-050936:0
Ideal exit: 21 May 2023 (T+270)
10,000 shares@ US$3.380.0035% mcap100.0% of flowCommon StockSEC:0001213900-22-027450:0
Ideal exit: 10 Feb 2023 (T+270)
207,469 shares0Common StockSEC:0001213900-22-025973:0
4,442 sharesClass A Common StockSEC:0001209191-22-028164:0
11,111 sharesClass A Common StockSEC:0001209191-22-016056:0
29,684 sharesClass A Common StockSEC:0001209191-22-014150:0
1,500 shares@ US$4.100.0001% mcap50.0% of flowClass A Common StockSEC:0001209191-21-067956:0
1,500 shares@ US$4.100.0001% mcap100.0% of flowClass A Common StockSEC:0001209191-21-067956
4,441 sharesClass A Common StockSEC:0001209191-21-031567
4,441 sharesClass A Common StockSEC:0001209191-21-031567:0
21 of 21 declarations
About Todisco Joseph
Joseph Todisco serves as Executive Vice President and Chief Executive Officer of Amneal Pharmaceuticals, Inc. and CorMedix Inc. In his roles, he leads the operations of both companies, setting the strategic vision and overseeing teams. Joseph has extensive experience in the pharmaceutical industry, contributing to growth and innovation.
